Last reviewed · How we verify
Kothala Himbutu Biscuit — Competitive Intelligence Brief
phase 3
Herbal alpha-glucosidase inhibitor
Alpha-glucosidase; possibly GLP-1 pathway
Endocrinology / Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Kothala Himbutu Biscuit (Kothala Himbutu Biscuit) — Rajarata University, Sri Lanka. Kothala Himbutu (Salacia reticulata) extract in biscuit form modulates postprandial glucose levels and may improve insulin sensitivity through inhibition of intestinal alpha-glucosidase enzymes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Kothala Himbutu Biscuit TARGET | Kothala Himbutu Biscuit | Rajarata University, Sri Lanka | phase 3 | Herbal alpha-glucosidase inhibitor | Alpha-glucosidase; possibly GLP-1 pathway |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Herbal alpha-glucosidase inhibitor class)
- Rajarata University, Sri Lanka · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Kothala Himbutu Biscuit CI watch — RSS
- Kothala Himbutu Biscuit CI watch — Atom
- Kothala Himbutu Biscuit CI watch — JSON
- Kothala Himbutu Biscuit alone — RSS
- Whole Herbal alpha-glucosidase inhibitor class — RSS
Cite this brief
Drug Landscape (2026). Kothala Himbutu Biscuit — Competitive Intelligence Brief. https://druglandscape.com/ci/kothala-himbutu-biscuit. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing